PASS: post-authorisation safety study
A post-authorisation safety study (PASS) is a study of an authorised medicine run to identify or quantify a safety risk or to test risk minimisation.
Also known as: post-authorization safety study, imposed PASS, non-interventional PASS
4 min readUpdated
Reviewed by Gosia Luksza, CEO at Regunaut
At a glance
- Legal basis
- Article 1(15) and Articles 107m to 107q of Directive 2001/83/EC
- Guidance
- GVP Module VIII
- Protocol review
- 60 days, by the PRAC or the national authority, for imposed non-interventional studies
- Final report
- Within 12 months of the end of data collection
How it works
Article 1(15) of Directive 2001/83/EC defines a post-authorisation safety study as any study relating to an authorised medicinal product conducted with the aim of identifying, characterising or quantifying a safety hazard, confirming the safety profile of the product, or measuring the effectiveness of risk management measures. A PASS can be a clinical trial or a non-interventional study. Interventional studies follow the clinical trials legislation. The pharmacovigilance rules in Articles 107m to 107q of the Directive and in GVP Module VIII are written for non-interventional studies, such as cohort and case-control studies in healthcare databases, registries and drug utilisation studies.
The first distinction is between imposed and voluntary studies. A study is imposed when an authority makes it a condition of the marketing authorisation, either when the authorisation is granted under Article 21a or afterwards under Article 22a, where concerns arise about the risks of an authorised product; Articles 9(4) and 10a of Regulation (EC) No 726/2004 do the same for centrally authorised products. In the risk management plan these are category 1 studies, or category 2 where they are specific obligations of a conditional authorisation or of one granted under exceptional circumstances. Studies required in the plan without being a condition of the authorisation are category 3. Voluntary studies are those a holder sponsors or conducts on its own initiative.
For an imposed non-interventional PASS the holder submits a draft protocol before the study starts. It goes to the PRAC, or to the national competent authority where a single Member State requested the study under Article 22a and it runs only there. Within 60 days the PRAC or the authority issues a letter endorsing the protocol, an objection with reasons, or a notification that the study is a clinical trial. The study may begin only once the written endorsement has been issued, and substantial amendments need the same approval before they are implemented. Annex III of Commission Implementing Regulation (EU) No 520/2012 sets the format of the protocol, the abstract and the final study report. Holders must enter imposed non-interventional studies, with the protocol and later the results, in the HMA-EMA Catalogue of real-world data studies, which replaced the EU PAS Register.
Article 107m applies to every non-interventional PASS that a holder initiates, manages or finances, voluntary or imposed. The study must not be performed where the act of conducting it promotes the use of the medicine. Payments to healthcare professionals are limited to compensation for time and expenses. The holder must monitor the data generated and consider what they mean for the benefit-risk balance, report anything that might change it to the authorities, and reflect the findings in the next PSUR.
What goes wrong
A study started before the written endorsement arrives; a protocol amendment made in the field and reported afterwards; milestones in the risk management plan that pass without a submission or a request to change them; a final report that arrives more than 12 months after data collection ended; results that never become a variation of the product information; and a study designed mainly to put the product in prescribers' hands, which the Directive prohibits. Slow recruitment is the most common practical problem, and it should be raised with the authority while the study is running, not explained in the final report.
Timing
Before the study
Draft protocol submitted to the PRAC, or to the national authority for a study requested by and run in one Member State.
Within 60 days
Letter of endorsement, objection with reasons, or notification that the study is a clinical trial.
After endorsement
Protocol sent to the authorities of the Member States where the study runs; the study is registered and may begin.
During the study
Substantial amendments are submitted and approved before they are implemented.
Within 12 months of the end of data collection
Final study report and abstract submitted, with a variation if the results affect the authorisation.
For an imposed non-interventional study, the PRAC or the national authority responds to the draft protocol within 60 days. The final study report, with an abstract, is due within 12 months of the end of data collection unless the authority has granted a written waiver. The PRAC then assesses the results and can recommend that the authorisation is varied, suspended or revoked. For centrally authorised products EMA describes an assessment of up to 74 days, followed by a Commission decision where the authorisation changes.
PASS: common questions
What is the difference between an imposed and a voluntary PASS?
An imposed PASS is a condition of the marketing authorisation, set by an authority under Article 21a or 22a of Directive 2001/83/EC or the equivalent provisions of Regulation (EC) No 726/2004, and the holder is obliged to carry it out. A voluntary PASS is one the holder sponsors or conducts on its own initiative. Only imposed non-interventional studies need the protocol endorsed in advance under Articles 107n to 107q; the general rules of Article 107m apply to both.
Does a PASS protocol need approval before the study starts?
Yes, if the study is non-interventional and imposed as a condition of the authorisation. The draft protocol goes to the PRAC, or to the national authority when one Member State requested the study and it runs only there, and the study may start only after a written endorsement, which is due within 60 days. Voluntary studies do not need this endorsement, although an authority can ask to see the protocol and progress reports.
Is a PASS a clinical trial?
It can be either. The legal definition covers any study of an authorised medicine with a safety objective. If the study assigns treatment or adds diagnostic or monitoring procedures beyond normal practice, it is a clinical trial and follows the clinical trials legislation. If it observes normal clinical practice, it is non-interventional and falls under Articles 107m to 107q of Directive 2001/83/EC and GVP Module VIII.